Navigation Links
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Date:12/3/2008

registration trial, 20% if OGX-011 is licensed prior to marketing approval and 15% thereafter. In addition, Isis currently owns approximately 2% of the outstanding common stock of OncoGenex.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' business, its drug discovery and development pipeline, and the therapeutic potential of OGX-011 for the treatment of cancer. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Pa., June 30, 2011 Endo Pharmaceuticals (Nasdaq: ... study comparing the novel investigational drug axomadol against placebo in ... back pain. The results indicate that axomadol did not meet ... analyses of the data and evaluating the path forward for ...
... 30, 2011 UCB and Harvard University officially launched ... took place in Boston last night in the presence ... (Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 ) The ... and academia, with Harvard scientists continuing their research that ...
Cached Medicine Technology:Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain 2UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3
(Date:7/10/2014)... (HealthDay News) -- Most professional football players who have ... game, a new study finds. Shoulder instability is ... of return after surgery to fix the problem has ... study included 60 players who had shoulder stabilization surgery. ... returned to play, defined as playing in at least ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... help ease the hot flashes that often accompany menopause, new ... than 50 percent of menopausal women, said Dr. Taraneh Shirazian, ... at the Icahn School of Medicine at Mount Sinai Hospital ... more than 10 hot flashes a day, and she added ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... of 10 adults make use of calorie information on menus, ... according to a new U.S. study. Women in particular ... Hee Lee-Kwan, an epidemiologist with the U.S. Centers for Disease ... they used menu labeling to help choose their meal, compared ...
(Date:7/10/2014)... than 200 experts on aggression, who research issues ranging ... the 21st World Meeting of the International Society for ... July 15-19. , Georgia State University is hosting the ... on alternating continents. , "We are excited to be ... countries, which will help produce fresh ideas about the ...
(Date:7/10/2014)... the top public health concerns in the United States, ... obese as of 2012. As health problems such as ... Twitter to discuss the problem. , A new study, ... the Brown School at Washington University in St. Louis, ... to track Twitter conversations about the issue of overweight ...
Breaking Medicine News(10 mins):Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:Study looks at how Twitter can be used to address specific health issues 2
... data from Understanding Society based on 14,000 UK households found ... higher levels of education and by married people. The ... with those in routine occupations reporting worse sleep than those ... University of Surrey who analysed the findings said: "Given the ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) -- ... seven hours a night, which affects their concentration and ... also impairs work performance and the ability to drive ... Control and Prevention (CDC), which published two sleep studies ...
... The combined effects of chemotherapy and endocrine therapy ... cancer survivors. In a study scheduled for publication in ... Medicine and Rehabilitation , researchers from the Oregon Health ... breast cancer survivors whether they had fallen in the ...
... An analysis of breast tissue may help doctors better predict ... Researchers analyzed what they describe as "highways" of connective ... collagen fibers -- the main component of connective tissue -- ... determine treatment. Collagen not only surrounds most body organs ...
... -- New findings about brain rhythms could lead to the ... A team at Massachusetts General Hospital found that a brain ... hidden form during sleep, where it becomes more intense at ... to being awakened by noise or other disturbances. To ...
... The burning, tingling pain of neuropathy may affect feet ... of nerve cells that supply the extremities age and ... these areas, Johns Hopkins scientists suggest in a new ... to fight neuropathy, a condition that often accompanies other ...
Cached Medicine News:Health News:The better off sleep better 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 3Health News:Breast cancer survivors at higher risk for falls 2Health News:Tissue Analysis May Help Predict Breast Cancer Outcome 2Health News:Particular Brain Rhythm in Sleep Makes You More Vulnerable to Disturbances 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 3
ELISA kit for CMV CAP M....
Cytomegalovirus IgG ELISA....
Cytomegalovirus IgM ELISA....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Medicine Products: